Dimensional Fund Advisors LP Buys 123,240 Shares of Zymeworks Inc. (NYSE:ZYME)

Dimensional Fund Advisors LP increased its position in shares of Zymeworks Inc. (NYSE:ZYME) by 14.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 972,742 shares of the company’s stock after acquiring an additional 123,240 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Zymeworks were worth $14,240,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Sterling Capital Management LLC boosted its position in shares of Zymeworks by 781.5% during the fourth quarter. Sterling Capital Management LLC now owns 1,719 shares of the company’s stock worth $25,000 after purchasing an additional 1,524 shares in the last quarter. AlphaQuest LLC raised its stake in Zymeworks by 480.2% during the 4th quarter. AlphaQuest LLC now owns 2,808 shares of the company’s stock worth $41,000 after buying an additional 2,324 shares during the period. KLP Kapitalforvaltning AS bought a new position in Zymeworks during the fourth quarter worth about $151,000. New York State Common Retirement Fund grew its stake in Zymeworks by 42.7% in the fourth quarter. New York State Common Retirement Fund now owns 13,371 shares of the company’s stock valued at $196,000 after acquiring an additional 4,000 shares during the period. Finally, Teacher Retirement System of Texas increased its holdings in shares of Zymeworks by 19.2% in the fourth quarter. Teacher Retirement System of Texas now owns 13,743 shares of the company’s stock worth $201,000 after acquiring an additional 2,216 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Insider Activity at Zymeworks

In other Zymeworks news, Director Ecor1 Capital, Llc purchased 22,689 shares of Zymeworks stock in a transaction that occurred on Monday, March 24th. The stock was acquired at an average price of $13.08 per share, for a total transaction of $296,772.12. Following the completion of the acquisition, the director now owns 17,157,802 shares of the company’s stock, valued at approximately $224,424,050.16. This trade represents a 0.13 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Over the last three months, insiders bought 1,350,347 shares of company stock valued at $16,137,499. 1.92% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Lifesci Capital started coverage on Zymeworks in a report on Tuesday, March 11th. They set an “outperform” rating and a $30.00 price objective on the stock. HC Wainwright upped their price target on shares of Zymeworks from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Monday, March 10th. Finally, Citigroup raised their price objective on shares of Zymeworks from $18.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, March 7th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Zymeworks Price Performance

Zymeworks stock opened at $11.32 on Friday. The firm has a 50-day moving average of $11.88 and a 200-day moving average of $13.46. The company has a market cap of $787.61 million, a price-to-earnings ratio of -7.55 and a beta of 1.24. Zymeworks Inc. has a one year low of $8.21 and a one year high of $17.70.

Zymeworks (NYSE:ZYME) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. The firm’s revenue was up 170.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.42) earnings per share. As a group, sell-side analysts expect that Zymeworks Inc. will post -1.39 earnings per share for the current year.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.